The Central Serous Chorioretinopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Central Serous Chorioretinopathy: An Overview
According to the American Society of Retina Specialists (ASRS), Central serous chorioretinopathy (CSC), is a condition in which fluid accumulates under the retina, particularly the macula, which is the middle area of the retina responsible for central vision, causing a serous (fluid-filled) detachment and vision loss.
CSC is typically a self-limiting disease, and visual recovery usually occurs within a few weeks to months without treatment. Several therapies have been used to treat chronic Central Serous Chorioretinopathy, including thermal laser treatments, oral medications, and eye injections.
Central Serous Chorioretinopathy Market Key Facts
According to the American Academy of Opthalmology (AAO), most patients who present with Central Serous Chorioretinopathy are between the ages of 28 to 68 years with an average age of 43 years. Those who are over 50 years of age are more likely to have bilateral disease (50%) with RPE loss and choroidal neovascularization compared to those less than 50 years of age (28.4%).
Sartini et al., (2019) conducted a study titled “Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options” stated that CSC especially affects Western European descent and Asian patients. Generally, CSCR resolves in 3–4 months, nevertheless, about 15% of patients develop a chronic form or non-resolving CSCR. This kind of patient is older compared to ones affected by acute Central Serous Chorioretinopathy.
The Central Serous Chorioretinopathy Market is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Central Serous Chorioretinopathy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Central Serous Chorioretinopathy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Central Serous Chorioretinopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Central Serous Chorioretinopathy Epidemiology Segmentation –
Prevalent Population of Central Serous Chorioretinopathy
Gender-specific Prevalent Population of Central Serous Chorioretinopathy
Age-specific Prevalent Population Central Serous Chorioretinopathy
Diagnosed and Treatable Cases of Central Serous Chorioretinopathy
Central Serous Chorioretinopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Central Serous Chorioretinopathy market or expected to get launched during the study period. The analysis covers Central Serous Chorioretinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Central Serous Chorioretinopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/central-serous-chorioretinopathy-market
Central Serous Chorioretinopathy Therapeutics Analysis
The Central Serous Chorioretinopathy (CSC) therapeutics pipeline is very narrow which reflects that there is a high medical unmet need for potential treatment options for the patients. The Central Serous Chorioretinopathy market dynamics is anticipated to change in the coming years owing to the progress in the research and development activities so that the market will comprise efficient treatment regimens.
Central Serous Chorioretinopathy is an enigmatic disease that is still not completely understood due to its multifactorial etiology, complex pathogenesis, and wide systemic associations. The pipeline for Central Serous Chorioretinopathy is not robust creating a high-medical unmet need for better treatment alternatives with prominent emerging drugs in the future.
Targeted Therapy Technologies is one of the key companies in the Central Serous Chorioretinopathy market involved in therapeutic development. Targeted Therapy Technologies is developing Episcleral Celecoxib for the treatment of Central Serous Chorioretinopathy. Celecoxib, a selective inhibitor of cyclooxygenase 2 enzyme, has been demonstrated to have anti-VEGF activity in the retinal cells.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/central-serous-chorioretinopathy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Central Serous Chorioretinopathy Competitive Intelligence Analysis
4. Central Serous Chorioretinopathy Market Overview at a Glance
5. Central Serous Chorioretinopathy Disease Background and Overview
6. Central Serous Chorioretinopathy Patient Journey
7. Central Serous Chorioretinopathy Epidemiology and Patient Population
8. Central Serous Chorioretinopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Central Serous Chorioretinopathy Unmet Needs
10. Key Endpoints of Central Serous Chorioretinopathy Treatment
11. Central Serous Chorioretinopathy Marketed Products
12. Central Serous Chorioretinopathy Emerging Therapies
13. Central Serous Chorioretinopathy Seven Major Market Analysis
14. Attribute Analysis
15. Central Serous Chorioretinopathy Market Outlook (7 major markets)
16. Central Serous Chorioretinopathy Access and Reimbursement Overview
17. KOL Views on the Central Serous Chorioretinopathy Market.
18. Central Serous Chorioretinopathy Market Drivers
19. Central Serous Chorioretinopathy Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/central-serous-chorioretinopathy-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Gene And Cell Therapies In Rare Disorder Market
“Gene And Cell Therapies In Rare Disorder Market” research report deliver an in-depth understanding of the historical and forecasted epidemiology, market size, share, and trends, as well as the emerging therapies and the key companies operating in the Gene And Cell Therapies In Rare Disorder Market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States